The Clinical and Experimental Therapeutics Program is a cohesive, integrated program with 51 members representing 9 departments. This is a broad program with the overall goal to foster interaction between basic and clinical investigators that will result in innovative and effective therapies for cancer patients. The scientific goals are to:
1) foster interaction between basic and clinical investigators that will result in innovative and effective therapies;
2) integrate new drugs into the development of multimodality therapies for patients with advanced solid tumors; and
3) pursue a broad program of preclinical, translational, and clinical research in pharmacogenetics and pharmacology.
The program has a long-standing focus on drug development at all phases of clinical testing and a strong pharmacogenetic component. The translational nature of much of the work emanating from this program and the leadership role assumed by many program faculty in studies conducted by national clinical cooperative groups illustrates the impact of this program in developing new therapies for oncology.
Program Highlights 2005 – 2007
Program 1
Cell Signaling and Gene Regulation
Program Leaders: Marsha Rosner, PhD and Suzanne Conzen, MD
Program 2
Molecular Genetics and Hematopoiesis
Program Leaders: Wendy Stock, MD and Michael Thirman, MD
Program 3
Immunology and Cancer
Program Leader: Thomas F. Gajewski, MD, PhD
Program 4
Clinical and Experimental Therapeutics
Program Leaders: Everett E. Vokes, MD and M. Eileen Dolan, PhD
Program 5
Advanced Imaging
Program Leaders: Maryellen L. Giger, PhD and Heber MacMahon, MD
Program 6
Cancer Risk and Prevention
Program Leaders: Olufunmilayo (Funmi) I. Olopade, MBBS and Andrea King, PhD
| The University of Chicago Cancer Research Center © 2005 The University of Chicago 5841 South Maryland Avenue, MC 1140, Chicago, IL 60637 773-702-6180 Contact Us | Maps & Directions | Sitemap |